7.10
-0.30 (-4.05%)
| Penutupan Terdahulu | 7.40 |
| Buka | 7.40 |
| Jumlah Dagangan | 8,504,920 |
| Purata Dagangan (3B) | 12,640,717 |
| Modal Pasaran | 7,436,213,248 |
| Harga / Jualan (P/S) | 48.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| Margin Operasi (TTM) | -390.08% |
| EPS Cair (TTM) | -0.570 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 41,192.50% |
| Nisbah Semasa (MRQ) | 2.22 |
| Aliran Tunai Operasi (OCF TTM) | -370.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -251.77 M |
| Pulangan Atas Aset (ROA TTM) | -55.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ImmunityBio, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.17 |
|
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 74.11% |
| % Dimiliki oleh Institusi | 9.33% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |